FFNS 110 mcg QD; FFNS 110 mcg BID; Placebo Nasal Spray
Проводит ГлаксоСмитКляйн ЛЛС
Страница компанииA Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, 2-week Treatment Study to Evaluate the Safety and Efficacy of Fluticasone Furoate Nasal Spray 110 mcg in the Treatment in the Treatment of Uncomplicated Acute Rhinosinusitis in Adults and Adolescents >= 12 Years of Age
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01018030/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 12 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 741 чел. во всех странах исследования.
- Плановая дата окончания (07.2010) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 20
Критерии включения
- Informed consent
- Outpatient
- Age (>= 18 years at Visit 1 for Russia, Ukraine, and Germany; >= 12 years at Visit 2 for all other countries)
- Diagnosis of uncomplicated acute rhinosinusitis
- Ability and willingness to comply with study procedures and restrictions.
- Male or eligible female - Female subjects should not be enrolled if they plan to become pregnant during the time of study participation; To be eligible for entry into the study, females of childbearing potential must commit to the consistent and correct use of an acceptable method of birth control.
- Literate
Критерии невключения
- Based on the investigator's clinical judgement, subject has fulminant bacterial rhinosinusitis during the screening period including Visits 1 and 2.
- A history of acute rhinosinusitis within 12 weeks prior to the current episode as determined by the investigator
- Current or a history of other sinonasal conditions (e.g., chronic or recurrent rhinosinusitis, non-allergic rhinitis) within 3 years prior to Visit 1 as determined by the investigator
- Symptomatic perennial or seasonal allergic rhinitis prior to ARS episode, or allergy to seasonal allergens likely to be present during the study period (as determined by documented skin prick test or in vitro blood test).
- Significant concomitant medical conditions
- Subjects with planned elective surgery, vacation or other event during the study period which could prevent the subject from participating in the study according to protocol specifications
- Use of antibiotics within 30 days prior to Visit 1 for sinopulmonary infections.
- Use of antiviral medications such as zanamivir and oseltamivir within 30 days prior to Visit 1
- Use of analgesics or antipyretics within 1 day prior to Visit 1
- Known hypersensitivity or allergy to corticosteroids or any excipients in the product
- Use of corticosteroids, defined as:
- Use of any other medications that may affect nasal symptoms
- Use of immunosuppressive medications eight weeks prior to screening and during the study
- Immunotherapy
- Use of any medications that significantly inhibit the cytochrome P450 subfamily enzyme CYP3A4, including ritonavir and ketoconazole
- Clinical trial/experimental medication experience
- Positive pregnancy test or inconclusive pregnancy test or female who is breastfeeding
- Affiliation with investigational site
- Current tobacco use
- Chicken pox or measles
Источник: ClinicalTrials.gov, NCT01018030 · запись обновлена в реестре 17 мая 2017.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 13
- Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period (Weeks 1-2) — Baseline and entire treatment period (up to 2 weeks)
Цель исследования
The purpose of this study is to assess the safety and efficacy of fluticasone furoate nasal spray (FFNS), without the use of an antibiotic, in the treatment of adult and adolescent subjects who are 12 years of age and older with uncomplicated acute rhinosinusitis (ARS).
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01018030 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.